Publicacións (173) Publicacións de Roberto Barriales Villa

filter_list

2025

  1. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

    JACC: Heart Failure, Vol. 13, Núm. 8

  2. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.

    New England Journal of Medicine, Vol. 393, Núm. 10, pp. 949-960

  3. Clinical management and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy in Spain: a real-world study

    Revista Espanola de Cardiologia

  4. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy

    JACC: Heart Failure

  5. Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial

    Journal of the American College of Cardiology

  6. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM

    Journal of the American College of Cardiology

  7. Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial

    Journal of the American College of Cardiology

  8. Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiomyopathies in low-resource settings

    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES

  9. Left ventricular ejection fraction decline and cardiovascular events in suspected cardiomyopathy with excessive trabeculation: toward precision medicine

    Revista Espanola de Cardiologia, Vol. 78, Núm. 11, pp. 934-944

  10. Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM

    ESC Heart Failure

  11. Pregnancy in women with dilated cardiomyopathy genetic variants

    Revista Espanola de Cardiologia, Vol. 78, Núm. 1, pp. 2-9

  12. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants

    Circulation, Vol. 152, Núm. 15, pp. 1060-1075

  13. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

    Journal of the American Heart Association, Vol. 14, Núm. 6, pp. e038758

  14. Sex Differences in Children and Adolescents With Hypertrophic Cardiomyopathy

    JACC-ADVANCES, Vol. 4, Núm. 8

  15. The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy

    JACC: Heart Failure

2024

  1. A cost-effectiveness analysis of hypertrophic cardiomyopathy sudden cardiac death risk algorithms for implantable cardioverter defibrillator decision-making

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 10, Núm. 4, pp. 285-293

  2. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial

    JAMA Cardiology

  3. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

    The New England journal of medicine, Vol. 390, Núm. 20, pp. 1849-1861

  4. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial

    European Heart Journal, Vol. 45, Núm. 42, pp. 4464-4478

  5. Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy

    Journal of the American Heart Association, Vol. 13, Núm. 21, pp. e036208